Boston Globe | Rescheduling marijuana opens opportunity for research, tax fairness

The Editorial Board of the Boston Globe reports on the recent executive order Donald Trump signed 12/18 to expedite the reclassification of marijuana. Reclassifying cannabis from Schedule I to Schedule III drug will move it from a category that include "dangerous drugs that have no accepted medical use", to a category of drugs "which have 'moderate to low' potential for dependence and have an accepted medical use" like ketamine, steroids, and testosterone. This reclassification could impact "an inequity in the federal tax code that forbids state-licensed marijuana companies like growers and dispensaries from writing off business expenses"as well as potentially eliminate regulatory barriers for researchers.

"Massachusetts should be leading the pack in terms of cannabis and cannabinoid-based research," says Dr. Gruber. "We have all the requisite tools, institutions, and individuals who are well-ensconced in this arena."

Read the Boston Globe article here.